NCT01455870

Brief Summary

Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
535

participants targeted

Target at P50-P75 for phase_3 type-2-diabetes

Timeline
Completed

Started May 2013

Typical duration for phase_3 type-2-diabetes

Geographic Reach
5 countries

54 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 18, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 20, 2011

Completed
1.5 years until next milestone

Study Start

First participant enrolled

May 1, 2013

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2015

Completed
Last Updated

June 2, 2016

Status Verified

May 1, 2016

Enrollment Period

2.2 years

First QC Date

October 18, 2011

Last Update Submit

May 13, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in HbA1c between Week 52 and Day 0

    52 weeks

Study Arms (2)

ITCA 650 60 mcg/day

EXPERIMENTAL

ITCA 650 is exenatide in DUROS

Drug: ITCA 650 60 mcg/day

sitagliptin

ACTIVE COMPARATOR

sitagliptin 100 mg/day

Drug: sitagliptin

Interventions

exenatide in DUROS

ITCA 650 60 mcg/day

oral sitagliptin 100 mg/day

sitagliptin

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • HbA1c between 7.5% - 10.5%
  • on metformin monotherapy
  • BMI between 25 \& 45 kg/m2

You may not qualify if:

  • taking thiazolidinedione, sulfonylurea, DPP-4, exenatide, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months
  • history of pancreatitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (54)

Unknown Facility

Birmingham, Alabama, 35235, United States

Location

Unknown Facility

Chandler, Arizona, 85224, United States

Location

Unknown Facility

Long Beach, California, 90807, United States

Location

Unknown Facility

Los Angeles, California, 90017, United States

Location

Unknown Facility

San Diego, California, 92101, United States

Location

Unknown Facility

San Mateo, California, 94401, United States

Location

Unknown Facility

Tustin, California, 92780, United States

Location

Unknown Facility

Valley Village, California, 91607, United States

Location

Unknown Facility

Walnut Creek, California, 94598, United States

Location

Unknown Facility

Boca Raton, Florida, 33432, United States

Location

Unknown Facility

Clearwater, Florida, 33765, United States

Location

Unknown Facility

Coral Gables, Florida, 33134, United States

Location

Unknown Facility

Miami, Florida, 33126, United States

Location

Unknown Facility

North Miami Beach, Florida, 33162, United States

Location

Unknown Facility

Pembroke Pines, Florida, 33026, United States

Location

Unknown Facility

Canton, Georgia, 30114, United States

Location

Unknown Facility

Chicago, Illinois, 60607, United States

Location

Unknown Facility

Chicago, Illinois, 60634, United States

Location

Unknown Facility

Avon, Indiana, 46123, United States

Location

Unknown Facility

Franklin, Indiana, 46131, United States

Location

Unknown Facility

Greenfield, Indiana, 46140, United States

Location

Unknown Facility

Muncie, Indiana, 47304, United States

Location

Unknown Facility

Valparaiso, Indiana, 46383, United States

Location

Unknown Facility

Wichita, Kansas, 67205, United States

Location

Unknown Facility

Wichita, Kansas, 67208, United States

Location

Unknown Facility

Metairie, Louisiana, 70006, United States

Location

Unknown Facility

Brockton, Massachusetts, 2301, United States

Location

Unknown Facility

Traverse City, Michigan, 49684, United States

Location

Unknown Facility

Troy, Michigan, 48098, United States

Location

Unknown Facility

St Louis, Missouri, 63110, United States

Location

Unknown Facility

Billings, Montana, 59101, United States

Location

Unknown Facility

Lincoln, Nebraska, 68510, United States

Location

Unknown Facility

Las Vegas, Nevada, 89148, United States

Location

Unknown Facility

Brooklyn, New York, 11218, United States

Location

Unknown Facility

Endwell, New York, 13760, United States

Location

Unknown Facility

Morehead City, North Carolina, 28557, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27103, United States

Location

Unknown Facility

Cincinnati, Ohio, 45227, United States

Location

Unknown Facility

Kettering, Ohio, 45429, United States

Location

Unknown Facility

Norman, Oklahoma, 73069, United States

Location

Unknown Facility

Bend, Oregon, 97701, United States

Location

Unknown Facility

Uniontown, Pennsylvania, 15401, United States

Location

Unknown Facility

Memphis, Tennessee, 38119, United States

Location

Unknown Facility

Corpus Christi, Texas, 78414, United States

Location

Unknown Facility

Dallas, Texas, 75230, United States

Location

Unknown Facility

Dallas, Texas, 75390, United States

Location

Unknown Facility

Houston, Texas, 77083, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

Sugar Land, Texas, 77478, United States

Location

Unknown Facility

Tomball, Texas, 77375, United States

Location

Unknown Facility

Rijeka, 51000, Croatia

Location

Unknown Facility

Hvidovre, 2650, Denmark

Location

Unknown Facility

Bad Lauterberg im Harz, Lower Saxony, 37431, Germany

Location

Unknown Facility

Riga, LV1002, Latvia

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

ExenatideSitagliptin Phosphate

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

PeptidesAmino Acids, Peptides, and ProteinsVenomsComplex MixturesToxins, BiologicalBiological FactorsTriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPyrazines

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 18, 2011

First Posted

October 20, 2011

Study Start

May 1, 2013

Primary Completion

July 1, 2015

Study Completion

July 1, 2015

Last Updated

June 2, 2016

Record last verified: 2016-05

Locations